Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 2/2012

01.06.2012 | Management of Heart Failure (T Meyer, Section Editor)

Skeletal Muscle Abnormalities in Chronic Heart Failure

verfasst von: Panagiota Georgiadou, Stamatis Adamopoulos

Erschienen in: Current Heart Failure Reports | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Skeletal muscle abnormalities are well-established in patients with heart failure from an early stage in the progression of the disease and contribute to their symptoms and the limitation of physical activity. Heart failure–induced skeletal muscle pathology includes morphologic, histologic, and enzymatic changes along with derangements in skeletal muscle metabolism and autonomic function. These alterations influence both peripheral and ventilatory muscles, are present at rest, and deteriorate during exercise and their occurrence depends upon the severity and the duration of CHF syndrome. Future studies will be needed to elucidate the origin of skeletal “myopathy” and its reversibility, which is associated with improvement in exercise capacity, observed after physical training programs.
Literatur
1.
Harrington D, Anker SD, Coats AJ. Preservation of exercise capacity and lack of peripheral changes in asymptomatic patients with severely impaired left ventricular function. Eur Heart J. 2001;22:392–9.PubMedCrossRef
2.
Adamopoulos S, Coats AJ. Peripheral abnormalities in chronic heart failure. Postgrad Med J. 1991;67 Suppl 1:S74–9. discussion S79–80.PubMed
3.
Nicoletti I, Cicoira M, Zanolla L, et al. Skeletal muscle abnormalities in chronic heart failure patients: relation to exercise capacity and therapeutic implications. Congest Heart Fail. 2003;9:148–54.PubMedCrossRef
4.
Steinborn W, Anker S. Cardiac cachexia: pathophysiology and clinical implications. Basic Appl Myol. 2003;13:191–201.
5.
Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachex Sarcopenia Muscle. 2010;1:9–21.CrossRef
6.
Rolland Y, Abellan van Kan G, Gillette-Guyonnet S, Vellas B. Cachexia versus sarcopenia. Curr Opin Clin Nutr Metab Care. 2011;14:15–21.PubMedCrossRef
7.
Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20:683–93.PubMedCrossRef
8.
Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112:1756–62.PubMedCrossRef
9.
Gruson D, Ahn SA, Ketelslegers JM, Rousseau MF. Increased plasma myostatin in heart failure. Eur J Heart Fail. 2011;13:734–6.PubMedCrossRef
10.
Schulze PC, Gielen S, Adams V, et al. Muscular levels of proinflammatory cytokines correlate with a reduced expression of insulinlike growth factor-I in chronic heart failure. Basic Res Cardiol. 2003;98:267–74.PubMed
11.
Hambrecht R, Schulze PC, Gielen S, et al. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2002;39:1175–81.PubMedCrossRef
12.
Latres E, Amini AR, Amini AA, et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem. 2005;280:2737–44.PubMedCrossRef
13.
Schulze PC, Fang J, Kassik KA, et al. Transgenic overexpression of locally acting IGF-1 inhibits ubiquitin-mediated muscle atrophy in chronic left ventricular dysfunction. Circ Res. 2005;97:418–26.PubMedCrossRef
14.
Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117:399–412.PubMedCrossRef
15.
Du J, Wang X, Miereles C, et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest. 2004;113:115–23.PubMed
16.
• Conraads VM, Hoymans VY, Vermeulen T, et al. Exercise capacity in chronic heart failure patients is related to active gene transcription in skeletal muscle and not apoptosis. Eur J Cardiovasc Prev Rehabil. 2009;16:325–32. This study disputed the findings of skeletal muscle apoptosis in CHF patients and showed a relation between the level of active gene transcription/splicing and exercise performance. PubMedCrossRef
17.
Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol. 1999;33:959–65.PubMedCrossRef
18.
Adamopoulos S, Coats AJ, Brunotte F, et al. Physical training improves skeletal muscle metabolism in patients with chronic heart failure. J Am Coll Cardiol. 1993;21:1101–6.PubMedCrossRef
19.
Gielen S, Adams V, Möbius-Winkler S, et al. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol. 2003;3(42):861–8.CrossRef
20.
Hambrecht R, Schulze PC, Gielen S, et al. Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2005;12:401–6.PubMedCrossRef
21.
• Scarlett JM, Bowe DD, Zhu X, et al. Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure. J Endocrinol. 2010;206:121–30. This study was the first to reveal a key role for the central melanocortin system in the pathogenesis of cardiac cachexia. PubMedCrossRef
22.
• Heineke J, Auger-Messier M, Xu J, et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation. 2010;121:419–25. This was the first report on the local production of myostatin within skeletal muscle as a dominant regulator of developmental growth and hypertrophy in adulthood. PubMedCrossRef
23.
Anker SD, Coats AJ. How to recover from renaissance? the significance of the results of recover, renaissance, renewal and attach. Int J Cardiol. 2002;86:123–30.PubMedCrossRef
24.
Nilsson KR, Duscha BD, Hranitzky PM, Kraus WE. Chronic heart failure and exercise intolerance: the hemodynamic paradox. Curr Cardiol Rev. 2008;4:92–100.PubMedCrossRef
25.
Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation. 1990;81:518–27.PubMedCrossRef
26.
Drexler H, Riede U, Munzel T, et al. Alterations of skeletal muscle in chronic heart failure. Circulation. 1992;85:1751–9.PubMed
27.
Mancini DM, Coyle E, Coggan A, et al. Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle abnormalities in patients with chronic heart failure. Circulation. 1989;80:1338–46.PubMedCrossRef
28.
Ventura-Clapier R, De Sousa E, Veksler V. Metabolic myopathy in heart failure. News Physiol Sci. 2002;17:191–6.PubMed
29.
Duscha BD, Annex BH, Keteyian SJ, et al. Differences in skeletal muscle between men and women with chronic heart failure. J Appl Physiol. 2001;90:280–6.PubMed
30.
Tyni-Lenne R, Jansson E, Sylven C. Female-related skeletal muscle phenotype in patients with moderate chronic heart failure before and after dynamic exercise training. Cardiovasc Res. 1999;42:99–103.PubMedCrossRef
31.
Kiilavuori K, Näveri H, Salmi T, Härkönen M. The effect of physical training on skeletal muscle in patients with chronic heart failure. Eur J Heart Fail. 2000;2:53–63.PubMedCrossRef
32.
Schulze PC, Linke A, Schoene N, et al. Functional and morphological skeletal muscle abnormalities correlate with reduced electromyographic activity in chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2004;11:155–61.PubMedCrossRef
33.
Larsen AI, Skadberg Ø, Aarsland T, et al. B-type natriuretic peptide is related to histological skeletal muscle abnormalities in patients with chronic heart failure. Int J Cardiol. 2009;136:358–62.PubMedCrossRef
34.
Kindig C, Musch T, Basaraba R, Poole D. Impaired capillary hemodynamics in skeletal muscle of rats in chronic heart failure. J Appl Physiol. 1999;87:652–60.PubMed
35.
Duscha BD, Annex BH, Green HJ, Pippen AM, Kraus WE. Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure. J Am Coll Cardiol. 2002;39:1170–4.PubMedCrossRef
36.
Sullivan MJ, Green HJ, Cobb FR. Altered skeletal muscle metabolic response to exercise in chronic heart failure. Relation to skeletal muscle aerobic enzyme activity. Circulation. 1991;84:1597–607.PubMed
37.
Massie BM, Conway M, Yonge R, et al. 31-P nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in patients with congestive heart failure. Am J Cardiol. 1987;60:309–15.PubMedCrossRef
38.
De Sousa E, Lechêne P, Fortin D, N'Guessan B, Belmadani S, Bigard X, Veksler V, Ventura-Clapier R. Cardiac and skeletal muscle energy metabolism in heart failure: beneficial effects of voluntary activity. Cardiovasc Res. 2002;56:260–8.PubMedCrossRef
39.
Hambrecht R, Adams V, Gielen S, et al. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. J Am Coll Cardiol. 1999;33:174–9.PubMedCrossRef
40.
Schulze PC, Gielen S, Schuler G, Hambrecht R. Chronic heart failure and skeletal muscle catabolism: effects of exercise training. Int J Cardiol. 2002;85:141–9.PubMedCrossRef
41.
Brunotte F, Thompson CH, Adamopoulos S, et al. Rat skeletal muscle metabolism in experimental heart failure: effects of physical training. Acta Physiol Scand. 1995;154:439–47.PubMedCrossRef
42.
Scott AC, Wensel R, Davos CH, et al. Putative contribution of prostaglandin and bradykinin to muscle reflex hyperactivity in patients on Ace-inhibitor therapy for chronic heart failure. Eur Heart J. 2004;25:1806–13.PubMedCrossRef
43.
Scott AC, Wensel R, Davos CH, et al. Skeletal muscle reflex in heart failure patients: role of hydrogen. Circulation. 2003;107:300–6.PubMedCrossRef
44.
Piepoli M, Clark AL, Volterrani M, et al. Contribution of muscle afferents to hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure. Circulation. 1996;93:940–52.PubMed
45.
Ponikowski PP, Chua TP, Francis DP, et al. Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circulation. 2001;104:2324–30.PubMedCrossRef
46.
LeJemtel TH, Maskin CS, Lucido D, Chadwick BJ. Failure to augment maximal limb blood flow in response to one-leg versus two-leg exercise in patients with severe heart failure. Circulation. 1986;74:245–51.PubMedCrossRef
47.
Piepoli MF, Davos C, Francis DP, Coats AJ, ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). Br Med J. 2004;328:189–95.CrossRef
48.
Wong E, Selig S, Hare DL. Respiratory muscle dysfunction and training in chronic heart failure. Heart Lung Circ. 2011;20:289–94.PubMedCrossRef
49.
Meyer FJ, Borst MM, Zugck C, et al. Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation. 2001;103:2153–8.PubMed
50.
Winkelmann ER, Chiappa GR, Lima CO, et al. Addition of inspiratory muscle training to aerobic training improves cardiorespiratory responses to exercise in patients with heart failure and inspiratory muscle weakness. Am Heart J. 2009;158:768.e1–7.CrossRef
Metadaten
Titel
Skeletal Muscle Abnormalities in Chronic Heart Failure
verfasst von
Panagiota Georgiadou
Stamatis Adamopoulos
Publikationsdatum
01.06.2012
Verlag
Current Science Inc.
Erschienen in
Current Heart Failure Reports / Ausgabe 2/2012
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-012-0090-z

Weitere Artikel der Ausgabe 2/2012

Current Heart Failure Reports 2/2012 Zur Ausgabe

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (SD Katz, Section editor)

TNF Revisited: Osteoprotegerin and TNF-related Molecules in Heart Failure

Management of Heart Failure (TE Meyer, Section editor)

Role of Heart Rate as a Marker and Mediator of Poor Outcome for Patients with Heart Failure

Management of Heart Failure (T Meyer, Section Editor)

A Rational Approach to Assess Volume Status in Patients with Decompensated Heart Failure

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (SD Katz, Section editor)

The Neurohormonal Network in the RAAS Can Bend Before Breaking

Management of Heart Failure (TE Meyer, Section editor)

Cardiac Ultrasound Imaging in Heart Failure: Recent Advances

Management of Heart Failure (T. Meyer, Section Editor)

Prognostic Value of Combining Echocardiography and Natriuretic Peptide Levels in Patients with Heart Failure

Neu im Fachgebiet Kardiologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise